291 related articles for article (PubMed ID: 29843676)
41. Negative impact of self-stigmatization on attitude toward medication adherence in patients with psychosis.
Uhlmann C; Kaehler J; Harris MS; Unser J; Arolt V; Lencer R
J Psychiatr Pract; 2014 Sep; 20(5):405-10. PubMed ID: 25226204
[TBL] [Abstract][Full Text] [Related]
42. [Metabolic side effects of risperidone in early onset schizophrenia].
Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
[TBL] [Abstract][Full Text] [Related]
43. [Therapeutic alliance, a stake in schizophrenia].
Charpentier A; Goudemand M; Thomas P
Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998
[TBL] [Abstract][Full Text] [Related]
44. Attitudes toward antipsychotic medications as a useful feature in exploring medication non-adherence in schizophrenia.
Samalin L; de Chazeron I; Blanc O; Brunel L; Fond G; Llorca PM
Schizophr Res; 2016 Dec; 178(1-3):1-5. PubMed ID: 27637362
[TBL] [Abstract][Full Text] [Related]
45. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia.
Liu-Seifert H; Osuntokun OO; Feldman PD
Compr Psychiatry; 2012 Jan; 53(1):107-15. PubMed ID: 21310400
[TBL] [Abstract][Full Text] [Related]
46. Are we addressing the 'right stuff' to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication.
Beck EM; Cavelti M; Kvrgic S; Kleim B; Vauth R
Schizophr Res; 2011 Oct; 132(1):42-9. PubMed ID: 21820875
[TBL] [Abstract][Full Text] [Related]
47. Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization.
Jiang Y; Ni W
Pharmacotherapy; 2015 Sep; 35(9):813-22. PubMed ID: 26406773
[TBL] [Abstract][Full Text] [Related]
48. The effect of financial incentives on patients' motivation for treatment: results of "Money for Medication," a randomised controlled trial.
Noordraven EL; Wierdsma AI; Blanken P; Bloemendaal AFT; Mulder CL
BMC Psychiatry; 2018 May; 18(1):144. PubMed ID: 29793451
[TBL] [Abstract][Full Text] [Related]
49. Stigma, discrimination and medication adherence in schizophrenia: results from the Swedish COAST study.
Brain C; Sameby B; Allerby K; Quinlan P; Joas E; Lindström E; Burns T; Waern M
Psychiatry Res; 2014 Dec; 220(3):811-7. PubMed ID: 25457284
[TBL] [Abstract][Full Text] [Related]
50. Perspectives on reasons for non-adherence to medication in persons with schizophrenia in Ethiopia: a qualitative study of patients, caregivers and health workers.
Teferra S; Hanlon C; Beyero T; Jacobsson L; Shibre T
BMC Psychiatry; 2013 Jun; 13():168. PubMed ID: 23773362
[TBL] [Abstract][Full Text] [Related]
51. Methodological challenges in psychiatric treatment adherence research.
Velligan D; Sajatovic M; Valenstein M; Riley WT; Safren S; Lewis-Fernandez R; Weiden P; Ogedegbe G; Jamison J
Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):74-91. PubMed ID: 20643631
[TBL] [Abstract][Full Text] [Related]
52. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
[TBL] [Abstract][Full Text] [Related]
53. A large-scale validation study of the Medication Adherence Rating Scale (MARS).
Fialko L; Garety PA; Kuipers E; Dunn G; Bebbington PE; Fowler D; Freeman D
Schizophr Res; 2008 Mar; 100(1-3):53-9. PubMed ID: 18083007
[TBL] [Abstract][Full Text] [Related]
54. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
55. How do socio-demographic and clinical factors interact with adherence attitude profiles in schizophrenia? A cluster-analytical approach.
Beck EM; Cavelti M; Wirtz M; Kossowsky J; Vauth R
Psychiatry Res; 2011 May; 187(1-2):55-61. PubMed ID: 21074860
[TBL] [Abstract][Full Text] [Related]
56. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
[TBL] [Abstract][Full Text] [Related]
57. Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia.
Yang J; Ko YH; Paik JW; Lee MS; Han C; Joe SH; Jung IK; Jung HG; Kim SH
Schizophr Res; 2012 Feb; 134(2-3):226-31. PubMed ID: 22133906
[TBL] [Abstract][Full Text] [Related]
58. Reliability and validity of the Medication Adherence Rating Scale in a cohort of patients with schizophrenia from Nigeria.
Owie GO; Olotu SO; James BO
Trends Psychiatry Psychother; 2018; 40(2):85-92. PubMed ID: 29768528
[TBL] [Abstract][Full Text] [Related]
59. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
[TBL] [Abstract][Full Text] [Related]
60. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.
Perkins DO; Johnson JL; Hamer RM; Zipursky RB; Keefe RS; Centorrhino F; Green AI; Glick IB; Kahn RS; Sharma T; Tohen M; McEvoy JP; Weiden PJ; Lieberman JA;
Schizophr Res; 2006 Mar; 83(1):53-63. PubMed ID: 16529910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
